VAST VIEW Jefferies Upgrades Chemed Stock, Citing Hospice Growth and Margin Gains
Jefferies raised its rating on Chemed, pointing to growth in the company's hospice business and improving profit margins, according to Investing.com.
Investing.com News
Jefferies has upgraded its rating on Chemed, the healthcare services company known for its VITAS hospice division, according to Investing.com. The investment bank cited expansion in Chemed's hospice operations along with gains in profit margins as reasons behind the more favorable outlook.
Investing.com reported the upgrade without providing additional detail on the specific rating change, price target, or timeline cited by Jefferies analysts.
Limited Details Available
No further information on Chemed's financial performance or market reaction was included in the available reporting at this time.
Sources: Investing.com News
More from Money
The bar is higher for software companies now that their stocks have been outperforming, but analysts identify some top picks whose results could shine through.
Heating-oil prices are at record highs. Washington’s answer is a loan you will never see and a pipeline that does not exist.